A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Aims To examine baseline characteristics of patients recruited into ADOPT, a multinational trial comparing three oral glucose‐lowering monotherapies. Methods Between April 2000 and June 2002, 4360 patients aged 30–75 years with Type 2 diabetes diagnosed for < 3 years and remaining on diet therapy alone with fasting plasma glucose levels (FPG) between 7.0 and 10.0 mmol/l were enrolled by 488 North American and European centres. Medical histories, anthropometric data and laboratory measurements were determined using common methodologies. Results The mean (sd) age of the patients was 57 (10) years, body mass index 32.2 (6.4) kg/m 2, HbA 1c 7.4 (0.9)%; 58% were male, 88% Caucasian and 15% smoked. North American Caucasians (NAC) were younger, more obese, and more insulin resistant than European Caucasians (EUC), but had better pancreatic B‐cell function. NAC had lower total, low‐density lipoprotein‐ and high‐density liporpotein‐cholesterol concentrations with higher triglyceride concentrations and were more often on lipid‐lowering treatment. They had lower blood pressure levels but were equally likely to be on antihypertensive treatment. Metabolic syndrome was more frequent and microalbuminuria less frequent in NAC. Within North America, NAC had lower HbA 1c concentrations than Blacks, Hispanics and Asians despite similar or higher FPG and 30‐min postchallenge glucose concentrations. Conclusions Caucasian North American and European ADOPT patients differ with respect to adiposity, insulin resistance and metabolic syndrome prevalence. North American Blacks, Hispanics and Asians had lower HbA 1c concentrations than NAC despite similar or higher glucose concentrations. These phenotypic differences may influence the progression of Type 2 diabetes and the response to initial oral glucose‐lowering monotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
Hanson, R. L., Pratley, R. E., Bogardus, C., Narayan, K. M. V., Roumain, J. M. L., Imperatore, G., Fagot-Campagna, A., Pettitt, D. J., Bennett, P. H., & Knowler, W. C. (2000) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010187 · Cited by 463
Distribution of HbA1c Levels For Children and Young Adults in the U.S.
Saaddine, J. B., Fagot-Campagna, A., Rolka, D., Narayan, K. M. V., Geiss, L., Eberhardt, M., & Flegal, K. M. (2002) · Diabetes Care · doi:10.2337/diacare.25.8.1326 · Cited by 177
Cited by
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Self-citationThe Lancet Commission on diabetes: using data to transform diabetes care and patient lives
Chan, J. C. N., Lim, L.-L., Wareham, N. J., Shaw, J. E., Orchard, T. J., Zhang, P., Lau, E. S. H., Eliasson, B., Kong, A. P. S., Ezzati, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32374-6 · Cited by 793
Self-citationHerman, W. H., & Cohen, R. M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1894 · Cited by 286
Self-citationRacial differences in glycemic markers: a cross-sectional analysis of community-based data
Selvin, E., Steffes, M. W., Ballantyne, C. M., Hoogeveen, R. C., Coresh, J., & Brancati, F. L. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-5-201103010-00004 · Cited by 196
Risk Factors for Mortality Among Patients With Diabetes
McEwen, L. N., Kim, C., Karter, A. J., Haan, M. N., Ghosh, D., Lantz, P. M., Mangione, C. M., Thompson, T. J., & Herman, W. H. (2007) · Diabetes Care · doi:10.2337/dc07-0305 · Cited by 121
“are more likely to be of nonwhite race/ethnicity, more obese, less likely to smoke, and more likely to be treated with effective lipidlowering medications (19).”
BackgroundSelf-citation
Metadata
- Authors
- Viberti, G., Lachin, J., Holman, R., Zinman, B., Haffner, S., Kravitz, B., Heise, M. A., Jones, N. P., O’Neill, M. C., Freed, M. I., Kahn, S. E., Herman, W. H., & for the ADOPT Study Group
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2006-11-17
- Volume
- 23
- Issue
- 12
- Pages
- 1289-1294
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W2023271144
- Cited by
- 56
- References
- 3
- FWCI
- 3.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe. https://app.cochat.ai/papers/10.1111/j.1464-5491.2006.02022.x
- The paper
- Viberti, G., Lachin, J., Holman, R., Zinman, B., Haffner, S., Kravitz, B., Heise, M. A., Jones, N. P., O’Neill, M. C., Freed, M. I., Kahn, S. E., Herman, W. H., & for the ADOPT Study Group. (2006). A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2006.02022.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.